MAY 2·Stock Titan→
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation
Tango Therapeutics director Lee Sung received 12,300 restricted stock units (RSUs) and an option for 5,200 shares as part of his board compensation. The RSUs will vest in three equal annual installments starting January 2, 2027, and the stock option, with an exercise price of $22.06, will vest monthly over three years beginning January 2, 2026, both contingent on his continued service. This transaction is classified as routine non-employee director compensation rather than open-market trading.
APR 29·Bitget▼
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%.
The Nasdaq Biotechnology Index experienced a decline of over 1.2%. Several constituent stocks saw significant drops, including Tango Therapeutics, Personalis, PTC Therapeutics, Foghorn, and Erasca. Conversely, some stocks like Biogen, Agios Pharmaceuticals, First Tracks Biotherapeutics, Design Therapeutics, and KalVista Pharmaceuticals recorded substantial gains.
